Research shows that individuals of East Asian and African descent are the populations that may be more susceptible to Stevens-Johnson syndrome following ues of certain drugs, and yet, by and large, drug manufacturers do not warn these populations of the added risk of developing SJS when taking their drugs. Drugs such as allopurinol, carbamazepine and phenytoin (Dilantin is the generic name) are tied to an increased risk of Stevens Johnson Syndrome but their labels do not provide adequate warnings.
Doctors Can Better Manage Patients With Adequate Warnings
Doctors often must weigh the risks versus the benefits of given drugs for particular patients under their care. Without these warnings, primary care physicians, internists and family care doctors cannot properly assess these risks for their patients and inform their patients of the risks, especially those who fall within groups most susceptible to SJS. Even if it is determined that the benefit to the patient outweighs the risks and the drug is prescribed, with proper warnings, doctors will know to monitor these patients more closely while they are taking the medication. Patients, without adequate knowledge, do not have the ability to choose a safer alternative or a non-pharmacologic therapy.
At-Risk Patients Should Consult With Their Doctors Regarding SJS Risks
If you are of East Asian or African descent and are taking Carbamazapene or Phenytoin, respectively, you should consult with your doctor right away to determine if you are at increased risk of developing Stevens-Johnson Syndrome.
If you have developed Stevens-Johnson Syndrome, contact an experienced Stevens-Johnson syndrome attorney to discuss your situation, evaluate the legal options available to you and determine the types of Stevens-Johnson Syndrome damages for which you may be entitled.
FreeAdvice acknowledge the attorneys and experts at Advocate Law Group, PC and Aylstock, Witkin, Kreis & Overholtz, PLLC, for their contributions to this article.